Clear-cell cancer of the ovary—is it chemosensitive?
Version of Record online: 9 MAY 2005
International Journal of Gynecological Cancer
Volume 15, Issue 3, pages 432–437, May 2005
How to Cite
Pather, S. and Quinn, M.A. (2005), Clear-cell cancer of the ovary—is it chemosensitive?. International Journal of Gynecological Cancer, 15: 432–437. doi: 10.1111/j.1525-1438.2005.15305.x
- Issue online: 9 MAY 2005
- Version of Record online: 9 MAY 2005
- Accepted for publication January 20, 2004
- clear-cell ovary adenocarcinoma;
Abstract. Pather S, Quinn MA. Clear-cell cancer of the ovary—is it chemosensitive? Int J Gynecol Cancer 2005;15:432–437.
The records of all patients with clear-cell ovarian cancer (CCC) who underwent complete surgical staging and chemotherapy between 1984 and 2001 were reviewed and 39 patients identified as suitable for study. The mean patient age was 56 years, and the stage distribution was as follows: stage I, 53%; stage II, 13%; stage III, 32%; and stage IV, 2%. One in three patients with stage I disease developed recurrent disease despite adjuvant chemotherapy. Seventy percent of tumors demonstrated a response to combination carboplatin and paclitaxel. Tumors which had either a partial response or failed to respond to first-line chemotherapy demonstrated no response to second-line nonplatinum chemotherapy. Endometriosis was identified in 31% of tumors, and 18% of patients developed deep venous thrombosis (DVT); however, neither endometriosis nor DVT was associated with a poorer outcome. CCC has a high recurrence rate in early-stage disease despite adjuvant treatment with cytotoxic chemotherapy. Advanced disease does respond to carboplatin and paclitaxel, which should be the chemotherapeutic regimen of choice. New second-line agents are urgently required.